Wir haben ausgewählte Abstracts von unseren Partnern für Sie zusammengestellt.
AbbVie
- POS0306 | Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: a double-blind, randomized, placebo-controlled phase 3 trial
- POS0081 | Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 select-psa 1 study
- POS0684 | Is upadacitinib capable of improving patient-reported outcomes of rheumatoid arthritis in a real-world setting? Results from the post-marketing observational upwards study
AMGEN
- POS1077 | Large Joint Involvement and Substantial Disease Burden in Patients with Oligoarticular and Polyarticular Psoriatic Arthritis in the Multinational UPLIFT Survey
- POS0309 | Are Patients’ and rheumatologists’ Perception of the Burden and Treatment of psoriatic Arthritis Aligned? Results From the UPLIFT Survey
- AB0884 | Disease Outcomes in Patients with Psoriatic Arthritis Completing 12 Months of Apremilast Treatment – Real-world Data from the REWARD Study, Publication in Abstract Book
Biogen
- AB0380 | Anti-TNF: originators vs biosimilars (SB4/ABP501), comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
- AB0348 | The PROPER Study: A 48-week analysis of a pan-EU real-world study of SB5 biosimilar following transition from reference adalimumab in patients with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis
- AB0341 | Efficacy and drug survival after multiple-switching from adalimumab originator to the biosimilars ABP501 and SB5: A real-life study
Eli Lilly (Suisse) SA
- POS0930 | Safety and efficacy of ixekizumab treatment in patients with axial spondyloarthritis: 3-year clinical trial results from the coast programme
- POS0666 | A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 12 Month Time to Discontinuation, Effectiveness and Patient Reported Outcome Data from the European Cohort
- POS0682 | Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from RA-BEYOND up to 7 years of treatment
GSK
- OP0147 | The SLE-DAS remission and low disease activity states discriminate drug from placebo and better health-related quality Of life: post-hoc analysis of the bliss-52 and bliss-76 phase iii trials
- POS0119 | SLE-DAS remission and low disease activity states are associated with improved health[1]related quality of life and fatigue: post-hoc analysis of the bliss-52 and bliss-76 phase iii trials
- POS0183 | The effect of belimumab on sri-4 response In multiple subgroups of patients with Systemic lupus erythematosus: results of a Large integrated analysis
Janssen-Cilag AG
- POS1015 | Safety of Guselkumab in Patients with Active Psoriatic Arthritis who are Bio-naïve or TNFiexperienced: Pooled Results From 4 Randomized Clinical Trials Through 2 Years
- POS1037 | Effect of Guselkumab, a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years
- POS1070 | Baseline Determinants of Pain Response in Patients with Psoriatic Arthritis Receiving Guselkumab
MSD Merck Sharp & Dohme AG
- POS0940 | Factors associated with long-term retention of treatment with golimumab in a large cohort of patients with rheumatic diseases, with up to 8 years of follow-up
- POS0947 | Long-term golimumab persistence: 5-year treatment retention data pooled from five phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Novartis Pharma Schweiz AG
- OP0260 | Responsiveness of a combined power doppler and greyscale ultrasound score for assessing synovitis at joint level in psoriatic arthritis patients with inadequate response to csdmards: data from the ultimate trial
- POS0299 | Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients ith non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a phase iii randomised trial
- OP0221 | Efficacy of secukinumab in enthesitis-related arthritis: results from a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (junipera)
Pfizer AG
- OP0052 | The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis with complete control of inflammation
- OP0264 | Impact of baseline cardiovascular risk on the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
- POS0519 | Relationship between disease activity and major adverse events in patients with rheumatoid arthritis on tofacitinib or tnf inhibitors: a post hoc analysis of oral surveillance